ifosfamide has been researched along with Carcinoma, Non-Small Cell Lung in 289 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 7.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| " Both have a dose-response relationship." | 6.68 | Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. ( de Wit, R; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1996) |
| "Patients with advanced adenocarcinoma of the lung with measurable or assessable disease received chemotherapy with mesna, ifosfamide, carboplatin, and etoposide (MICE)." | 3.69 | Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. ( Boerrigter, L; Mooi, WJ; Rodenhuis, S; Slebos, RJ; Top, B; van Zandwijk, N; van't Veer, L, 1997) |
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 3.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| "Ifosfamide is a chloro-isophosphoramide prodrug activated by hepatic Cytochrome P450 enzymes." | 2.82 | Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. ( Ahluwalia, D; Ferraro, DJ; Hart, CP; Jung, D; Liu, Q; Matteucci, MD; Sun, JD; Wang, Y, 2016) |
| "Paclitaxel was given at the dose of 200 mg/m iv in 3 hours, ifosfamide (with mesna) at the dose of 3 g/m and carboplatin at an area under the curve 5, on day 1, every 21 days for a total of six cycles in responding or stabilized patients." | 2.71 | Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer. ( Ardizzoni, A; Ariganello, O; Boni, C; Cafferata, MA; De Marinis, F; Meriggi, F; Neumaier, CE; Portalone, L; Rosso, R; Torri, V; Zaniboni, A, 2003) |
| "Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC." | 2.71 | Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003) |
| "Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease-related symptoms, World Health Organization performance status (PS), and quality of life (QoL)." | 2.71 | Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. ( Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N, 2003) |
| " In this study, one cycle of chemotherapy combined the following: ifosfamide: 3 g/m2 fixed dose (24-hour intravenous infusion) combined with mesna, day 1; gemcitabine: starting dose 1,000 mg/m2/d, escalating by 250 mg/m2 increments, days 1 and 15; cisplatin: starting dose 80 mg/m2, subsequently 100 mg/m2, day 15; in cohorts of at least 3 patients." | 2.71 | Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. ( Billiart, I; Bourgeois, H; Chabrun, V; Chieze, S; Daban, A; Ferrand, V; Germain, T; Lemerre, D; Meurice, JC; Tourani, JM, 2004) |
| " Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity." | 2.71 | A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. ( Berghmans, T; Corhay, JL; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Lecomte, J; Lothaire, P; Mommen, P; Ninane, V; Paesmans, M; Richez, M; Sculier, JP; Thiriaux, J; Van Houtte, P; Wackenier, P, 2004) |
| "Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients." | 2.71 | Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005) |
| " Peak concentration of 47 micrograms/ml was observed after 1 h." | 2.70 | Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients. ( Gasiorek, M; Kobylińska, K; Kobylińska, M; Koralewski, P; Sobik, B, 2001) |
| "Neutropenia was the dose limiting toxicity (G1=6%, G2=11%, G3=10%, G4=7%)." | 2.70 | Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. ( Camps, C; García, R; Maestu, I; Montalar, J; Morales, S; Segura, A; Torregrosa, D; Vadell, C; Yuste, AL, 2001) |
| " No toxic death was reported." | 2.70 | Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). ( Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Conte, PF; Neumaier, C; Prochilo, T; Rosso, R; Tibaldi, C, 2001) |
| " Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone." | 2.69 | Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000) |
| "Gemcitabine was administered at a dose of 1,000 mg/m2 on days 1, 8, and 15, followed by a 1-week rest, while ifosfamide was given at a dose of 1,500 mg/m2 on days 8 through 12." | 2.69 | Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer. ( Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ, 1998) |
| "Ifosfamide 4 g/m2 was given for 4 h by intravenous infusion on day 2." | 2.69 | Phase II study of paclitaxel (Taxol) and ifosfamide (Holoxan) in inoperable non-small-cell lung cancer. ( Thongprasert, S, 1998) |
| "The gemcitabine dose was escalated from 500 to 1200 mg/m2 on days 3 and 8 every third week." | 2.69 | Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study. ( De Filippis, S; Guerriero, G; Pompili, P; Rea, S; Recchia, F; Rosselli, M, 1999) |
| " The present retrospective analysis assessed two ways of dosing carboplatin: according to body surface area (mg/m2) or to the estimated targeted area under the concentration versus time curve (AUC)." | 2.69 | A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party. ( Alexopoulos, CG; Berchier, MC; Bureau, G; Giner, V; Klastersky, J; Koumakis, G; Lafitte, JJ; Lecomte, J; Mommen, P; Ninane, V; Paesmans, M; Sculier, JP; Thiriaux, J; Zacharias, C, 1999) |
| "Megestrol acetate 250 mg PO was administered throughout the duration of chemotherapy." | 2.69 | A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. ( Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H, 1998) |
| " MIP regimen was permanently suspended in 14 patients because of toxic events." | 2.68 | Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer. ( Baud, M; Bedin, A; Chouaid, C; Febvre, M; Lebeau, B; Urban, T, 1996) |
| "Ifosfamide was administered at a dose of 1." | 2.68 | Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. ( Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE, 1996) |
| " Both have a dose-response relationship." | 2.68 | Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. ( de Wit, R; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1996) |
| "The ongoing phase I study reported here sought to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin when given at specific times in combination with ifosfamide, mesna, and filgrastim." | 2.68 | Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1997) |
| "Phlebitis was observed in 15 of 30 patients (50%) who did not have central implantable venous systems." | 2.68 | Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. ( Amato, S; Barbieri, M; Cuevas, M; Dominguez, M; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Perez, J; Rodriguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Sabatini, C; Salvadori, M; Vallejo, C, 1996) |
| " The study design and dosing schedule are discussed in this report." | 2.68 | Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. ( Golomb, HM; Hoffman, PC; Masters, G; Mauer, AM; Vokes, EE; Watson, S, 1997) |
| "We have treated 26 consecutive chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer with an innovative regimen based on a 1-hour infusion of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 125 to 250 mg/m2, ifosfamide 3 g/m2 (with mesna), and carboplatin dosed to an area under the concentration-time curve of 5, every 21 days for a total of six cycles in responding or stabilized patients." | 2.68 | Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: preliminary results. ( Alghisi, A; Bozzola, G; Marini, G; Meriggi, F; Mutti, S; Pascarella, A; Rizzi, A; Zaniboni, A, 1997) |
| "Paclitaxel was escalated from 75 to 225 mg/m2 in 25-mg/m2 increments." | 2.68 | Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. ( Carey, RW; Elias, AD; Grossbard, ML; Herbst, R; Jacobs, C; Kwiatkowski, DJ; Leong, T; Lynch, C; Lynch, TJ; Skarin, AT; Strauss, GM, 1997) |
| "Gemcitabine was administered at a dose of 1,000 mg/m2 on days 1, 8, and 15 followed by a 1-week rest, while ifosfamide was given at a dose of 1,500 mg/m2 on day 8 and days 9 through 12." | 2.68 | A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. ( Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ, 1997) |
| "Paclitaxel dose levels were 135, 170, 200, 250, and 300 mg/m2." | 2.68 | Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer. ( Bitran, JD; Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE; Watson, S, 1995) |
| " The dosage of paclitaxel was escalated from 75 to 225 mg/m2." | 2.68 | A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. ( Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ, 1995) |
| "The early stages of bronchial carcinoma are still a domain of operative treatment." | 2.68 | [Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. ( Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N, 1995) |
| "Ifosfamide was therefore decreased to 1." | 2.68 | Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. ( Drinkard, LC; Golomb, HM; Hoffman, PC; Masters, GA; Samuels, BL; Vokes, EE; Watson, S, 1996) |
| "Verapamil 480 mg day-1 was given for 3 days starting 24 h prior to chemotherapy which consisted of bolus vindesine 7 mg followed by ifosfamide/mesna 5 g m-2 over 24 h, followed by mesna alone for a further 8 h." | 2.67 | Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. ( Cantwell, BM; Corris, PA; Harris, AL; Millward, MJ; Munro, NC; Robinson, A, 1993) |
| " Carboplatin dosing by the area under the curve (AUC) may minimize thrombocytopenia." | 2.67 | Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. ( Comis, R; Haas, N; Kilpatrick, D; Krigel, RL; Langer, C; Padavic, K; Palackdharry, CS, 1994) |
| "Ifosfamide has shown promising single-agent activity in non-small cell lung cancer." | 2.67 | Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report. ( Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M, 1992) |
| "Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC." | 2.42 | Ifosfamide in non-small cell lung cancer. ( Boni, C; Zanelli, F, 2003) |
| "Gemcitabine has a mild toxicity profile that allows it to be combined easily in triplet combinations with other doublets." | 2.40 | Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. ( Bunn, PA, 1999) |
| "Ifosfamide has been used in combination with several drugs including cisplatin, giving rise to multiple doublets and triplets including the ifosfamide-cisplatin-mitomycin regimen (Cullen's MIC regimen) that has been commonly used in Europe." | 2.40 | Ifosfamide in non-small-cell lung cancer. ( Balaña, C; Martin, C; Rosell, R, 1999) |
| "Paclitaxel has been used in combination with several other nonplatinum agents for the treatment of NSCLC." | 2.40 | Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. ( Langer, CJ; Socinski, MA, 1999) |
| "Ifosfamide has been in use for several decades and is generally considered to be one of the most effective drugs for the treatment of non-small cell lung cancer (NSCLC)." | 2.40 | Ifosfamide and docetaxel in non-small cell lung cancer. ( Büchholz, E; Drings, P; Manegold, C, 1998) |
| "Ifosfamide has been combined with gemcitabine in a phase I/II study." | 2.40 | Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. ( Steward, WP, 1998) |
| "Ifosfamide is an analogue of cyclophosphamide that is active against a variety of solid tumors, including non-small cell lung cancer." | 2.39 | Ifosfamide in non-small cell lung cancer. ( Johnson, DH, 1996) |
| " The purpose of the study was to determine the optimal dosage and the maximal tolerated dose (MTD) of a specified schedule of gemcitabine and ifosfamide." | 1.33 | Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. ( Aschroft, L; Baka, S; Blackhall, F; Buchholz, E; Lorigan, P; Manegold, C; Nagel, S; Schott-von-Römer, K; Thatcher, N, 2006) |
| " Similar dose-response curves were found for both metabolites." | 1.30 | Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. ( Brüggemann, SK; Kisro, J; Wagner, T, 1997) |
| "Ifosfamide has shown promising single-agent activity in non-small cell lung cancer (NSCLC)." | 1.28 | Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer. ( Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M, 1992) |
| "Ifosfamide has a similar spectrum of antitumor activity but has different pharmacokinetics that could provide advantages in efficacy." | 1.28 | Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991) |
| " A positive correlation was found between the elimination half-life of ifosfamide and age (r = 0." | 1.28 | The effect of age on the pharmacokinetics of ifosfamide. ( Cerny, T; Lind, MJ; Margison, JM; Thatcher, N; Wilkinson, PM, 1990) |
| " IFN-alpha nl alone at this dosage was shown to have some cytotoxic activity." | 1.27 | Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. ( Balkwill, FR; Carmichael, J; Fergusson, RJ; Smyth, JF; Wolf, CR, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (4.50) | 18.7374 |
| 1990's | 164 (56.75) | 18.2507 |
| 2000's | 102 (35.29) | 29.6817 |
| 2010's | 10 (3.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tiseo, M | 2 |
| Bordi, P | 1 |
| Bortesi, B | 1 |
| Boni, L | 4 |
| Boni, C | 6 |
| Baldini, E | 9 |
| Grossi, F | 2 |
| Recchia, F | 4 |
| Zanelli, F | 3 |
| Fontanini, G | 1 |
| Naldi, N | 1 |
| Campanini, N | 1 |
| Azzoni, C | 1 |
| Bordi, C | 1 |
| Ardizzoni, A | 10 |
| Koufos, N | 1 |
| Michailidou, D | 1 |
| Xynos, ID | 1 |
| Tomos, P | 1 |
| Athanasiadou, K | 1 |
| Kosmas, C | 6 |
| Tsavaris, N | 3 |
| Ozdemir, O | 1 |
| Ozdemir, P | 1 |
| Veral, A | 1 |
| Uluer, H | 1 |
| Ozhan, MH | 1 |
| Berghmans, T | 11 |
| Lafitte, JJ | 13 |
| Scherpereel, A | 5 |
| Paesmans, M | 12 |
| Lecomte, J | 9 |
| Marco, VG | 1 |
| Meert, AP | 6 |
| Leclercq, N | 4 |
| Sculier, JP | 15 |
| Zhou, Y | 1 |
| Xu, Y | 1 |
| Zhao, J | 1 |
| Zhong, W | 1 |
| Wang, M | 1 |
| Sun, JD | 1 |
| Liu, Q | 1 |
| Ahluwalia, D | 1 |
| Ferraro, DJ | 1 |
| Wang, Y | 1 |
| Jung, D | 1 |
| Matteucci, MD | 1 |
| Hart, CP | 1 |
| Azim, HA | 1 |
| Elattar, I | 1 |
| Loberiza, FR | 1 |
| Azim, H | 1 |
| Mok, T | 1 |
| Ganti, AK | 1 |
| Loriot, Y | 1 |
| Mordant, P | 1 |
| Deutsch, E | 1 |
| Olaussen, KA | 1 |
| Soria, JC | 1 |
| Lee, KW | 1 |
| Kim, YJ | 1 |
| Kim, JH | 2 |
| Bang, SM | 1 |
| Chung, JH | 1 |
| Lee, JS | 5 |
| Barone, C | 2 |
| Germano, D | 2 |
| Matano, E | 1 |
| Marini, G | 4 |
| Labianca, R | 1 |
| Di Costanzo, F | 4 |
| Bagnulo, A | 1 |
| Pennucci, C | 1 |
| Caroti, C | 1 |
| Mencoboni, M | 2 |
| Prochilo, T | 3 |
| Cafferata, MA | 4 |
| Giner, V | 9 |
| Berchier, MC | 8 |
| Lewin, D | 1 |
| Bosschaerts, T | 2 |
| Mouillet, G | 1 |
| Monnet, E | 1 |
| Milleron, B | 5 |
| Puyraveau, M | 2 |
| Quoix, E | 5 |
| David, P | 1 |
| Ducoloné, A | 1 |
| Molinier, O | 1 |
| Zalcman, G | 1 |
| Depierre, A | 6 |
| Westeel, V | 4 |
| Thiriaux, J | 8 |
| Florin, MC | 2 |
| Efremidis, A | 7 |
| Alexopoulos, CG | 7 |
| Recloux, P | 3 |
| Ninane, V | 12 |
| Mommen, P | 8 |
| Klastersky, J | 6 |
| Billingham, LJ | 3 |
| Bathers, S | 1 |
| Burton, A | 1 |
| Bryan, S | 1 |
| Cullen, MH | 7 |
| De Ruysscher, D | 2 |
| Lievens, Y | 2 |
| Van den Brande, P | 2 |
| Nackaerts, K | 2 |
| Vansteenkiste, J | 5 |
| Li, DX | 1 |
| Chen, XB | 1 |
| Souquet, PJ | 3 |
| Tan, EH | 4 |
| Rodrigues Pereira, J | 1 |
| Van Klaveren, R | 1 |
| Price, A | 1 |
| Gatzemeier, U | 5 |
| Jaworski, M | 1 |
| Burillon, JP | 1 |
| Aubert, D | 2 |
| Crinò, L | 7 |
| Lin, YC | 1 |
| Lin, Y | 1 |
| Lin, W | 1 |
| Du, CW | 1 |
| Wu, MY | 1 |
| Li, DR | 1 |
| Zaniboni, A | 4 |
| De Marinis, F | 5 |
| Portalone, L | 4 |
| Meriggi, F | 3 |
| Ariganello, O | 1 |
| Torri, V | 1 |
| Neumaier, CE | 1 |
| Rosso, R | 4 |
| Gebbia, V | 4 |
| Galetta, D | 4 |
| Caruso, M | 1 |
| Verderame, F | 1 |
| Pezzella, G | 1 |
| Valdesi, M | 1 |
| Borsellino, N | 1 |
| Pandolfo, G | 1 |
| Durini, E | 1 |
| Rinaldi, M | 3 |
| Loizzi, M | 1 |
| Gebbia, N | 3 |
| Valenza, R | 2 |
| Tirrito, ML | 1 |
| Varvara, F | 1 |
| Colucci, G | 4 |
| Chen, YM | 5 |
| Shih, JF | 2 |
| Lee, CS | 1 |
| Chen, MC | 1 |
| Lin, WC | 5 |
| Tsai, CM | 6 |
| Perng, RP | 7 |
| Mauer, AM | 4 |
| Ansari, RH | 1 |
| Hoffman, PC | 12 |
| Krauss, SA | 6 |
| Taber, D | 1 |
| Tembe, SA | 1 |
| Gabrys, GT | 1 |
| Cotter, T | 1 |
| Schumm, LP | 1 |
| Szeto, L | 1 |
| Vokes, EE | 13 |
| Ichiki, M | 1 |
| Rikimaru, T | 2 |
| Gohara, R | 1 |
| Koga, T | 1 |
| Kawayama, T | 1 |
| Matunami, M | 1 |
| Oshita, Y | 1 |
| Kamimura, T | 1 |
| Aizawa, H | 1 |
| Danson, S | 1 |
| Middleton, MR | 1 |
| O'Byrne, KJ | 1 |
| Clemons, M | 1 |
| Ranson, M | 1 |
| Hassan, J | 1 |
| Anderson, H | 3 |
| Burt, PA | 1 |
| Fairve-Finn, C | 1 |
| Stout, R | 1 |
| Dowd, I | 1 |
| Ashcroft, L | 5 |
| Beresford, C | 1 |
| Thatcher, N | 12 |
| Mohedano Mohedano, N | 1 |
| Sánchez Rovira, P | 1 |
| Lozano Barriuso, A | 1 |
| Fernandez Morales, M | 1 |
| Medina Magan, B | 1 |
| Jaen Morago, A | 1 |
| Porras Quintela, I | 1 |
| Dueñas Garcia, R | 1 |
| Fernandez Flores, E | 1 |
| Moreno Moreno, MA | 1 |
| Alberola, V | 1 |
| Camps, C | 5 |
| Provencio, M | 1 |
| Isla, D | 1 |
| Rosell, R | 9 |
| Vadell, C | 2 |
| Bover, I | 1 |
| Ruiz-Casado, A | 1 |
| Azagra, P | 1 |
| Jiménez, U | 1 |
| González-Larriba, JL | 1 |
| Diz, P | 1 |
| Cardenal, F | 1 |
| Artal, A | 3 |
| Carrato, A | 1 |
| Morales, S | 2 |
| Sanchez, JJ | 2 |
| de las Peñas, R | 1 |
| Felip, E | 1 |
| López-Vivanco, G | 1 |
| Fujita, A | 8 |
| Ohkubo, T | 1 |
| Hoshino, H | 1 |
| Takabatake, H | 6 |
| Tagaki, S | 6 |
| Sekine, K | 7 |
| Abe, S | 1 |
| Song, SY | 1 |
| Kim, WS | 1 |
| Kim, K | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Kim, HJ | 1 |
| Kang, WK | 1 |
| Lee, HG | 1 |
| Kwon, OJ | 1 |
| Rhee, CH | 1 |
| Park, CH | 1 |
| Park, K | 1 |
| Bourgeois, H | 2 |
| Billiart, I | 1 |
| Chabrun, V | 1 |
| Chieze, S | 1 |
| Lemerre, D | 1 |
| Germain, T | 1 |
| Ferrand, V | 1 |
| Meurice, JC | 2 |
| Daban, A | 1 |
| Tourani, JM | 2 |
| Van Houtte, P | 3 |
| Koumakis, G | 5 |
| Richez, M | 2 |
| Corhay, JL | 2 |
| Wackenier, P | 2 |
| Lothaire, P | 2 |
| Giaccone, G | 3 |
| Smit, EF | 1 |
| de Jonge, M | 1 |
| Dansin, E | 1 |
| Briasoulis, E | 1 |
| Douillard, JY | 2 |
| Spaeth, D | 1 |
| Lacombe, D | 1 |
| Baron, B | 1 |
| Bachmann, P | 2 |
| Fumoleau, P | 1 |
| Junker, K | 2 |
| Müller, KM | 1 |
| Abker, S | 1 |
| Bosse, U | 1 |
| Klinke, F | 2 |
| Thomas, M | 2 |
| VanHoutte, P | 1 |
| Lorent, N | 1 |
| De Leyn, P | 2 |
| Verbeken, E | 1 |
| Dooms, C | 1 |
| Van Raemdonck, D | 2 |
| Anrys, B | 1 |
| Rudd, RM | 2 |
| Gower, NH | 2 |
| Spiro, SG | 3 |
| Eisen, TG | 1 |
| Harper, PG | 2 |
| Littler, JA | 1 |
| Hatton, M | 1 |
| Johnson, PW | 1 |
| Martin, WM | 1 |
| Rankin, EM | 1 |
| James, LE | 1 |
| Gregory, WM | 1 |
| Qian, W | 1 |
| Lee, SM | 1 |
| Moro-Sibilot, D | 3 |
| Mercier, M | 1 |
| Breton, JL | 2 |
| Debieuvre, D | 1 |
| Richard, P | 1 |
| Haller, MA | 1 |
| Herman, D | 1 |
| Level, MC | 2 |
| Lebas, FX | 2 |
| Stephens, RJ | 1 |
| Girling, DJ | 1 |
| Hopwood, P | 1 |
| Braun, D | 2 |
| Lebeau, B | 5 |
| Boutemy, M | 1 |
| Mispelaere, D | 1 |
| Krzisch, C | 1 |
| Jounieaux, V | 1 |
| Govindan, R | 1 |
| Tho, LM | 1 |
| Ferry, DR | 2 |
| Lorusso, V | 1 |
| Spada, M | 1 |
| Guida, M | 1 |
| Cassano, G | 1 |
| Brunetti, C | 1 |
| Nettis, G | 1 |
| Izzi, G | 1 |
| Giampaglia, M | 1 |
| Silvestris, N | 1 |
| Koutras, A | 1 |
| Makatsoris, T | 2 |
| Mylonakis, N | 3 |
| Tzelepis, G | 1 |
| Dimitrakopoulos, A | 1 |
| Spyropoulos, K | 1 |
| Polyzos, A | 2 |
| Karabelis, A | 2 |
| Kalofonos, HP | 4 |
| Lee, HW | 1 |
| Choi, JH | 1 |
| Lim, HY | 1 |
| Park, JS | 1 |
| Kim, HC | 1 |
| Kang, S | 1 |
| Oh, YT | 1 |
| Chun, M | 1 |
| Sheen, SS | 1 |
| Oh, YJ | 1 |
| Park, KJ | 1 |
| Hwang, SC | 1 |
| Pujol, JL | 6 |
| Barlesi, F | 1 |
| Daurès, JP | 2 |
| Booton, R | 3 |
| Lorigan, P | 2 |
| Baka, S | 2 |
| Nicolson, M | 1 |
| O'Brien, M | 1 |
| Dunlop, D | 1 |
| O'Byrne, K | 1 |
| Laurence, V | 1 |
| Snee, M | 1 |
| Dark, G | 1 |
| Manegold, C | 7 |
| Buchholz, E | 2 |
| Schott-von-Römer, K | 1 |
| Nagel, S | 1 |
| Blackhall, F | 1 |
| Aschroft, L | 1 |
| Planchard, D | 1 |
| Adoun, M | 1 |
| Paitel, JF | 1 |
| Blanc, P | 1 |
| Genet, D | 1 |
| Ferru, A | 1 |
| Deletage, C | 1 |
| Cok, G | 1 |
| Göksel, T | 1 |
| Soyer, S | 1 |
| Atil, H | 1 |
| Güzelant, A | 1 |
| Aysan, T | 1 |
| Pohl, G | 1 |
| Krajnik, G | 1 |
| Malayeri, R | 1 |
| Müller, RM | 1 |
| Klepetko, W | 1 |
| Eckersberger, F | 2 |
| Schäfer-Prokop, C | 1 |
| Pokrajac, B | 1 |
| Schmeikal, S | 1 |
| Maier, A | 1 |
| Ambrosch, G | 1 |
| Woltsche, M | 1 |
| Minar, W | 1 |
| Pirker, R | 2 |
| Mardynskiĭ, IuS | 1 |
| Zolotkov, AG | 1 |
| Kudriavtsev, DV | 1 |
| Van Cutsem, O | 5 |
| Collon, T | 4 |
| Whang-Peng, J | 5 |
| Booten, R | 1 |
| Ward, T | 2 |
| Heighway, J | 2 |
| Morris, J | 2 |
| Grigorescu, A | 1 |
| Ciuleanu, T | 1 |
| Firoiu, E | 1 |
| Muresan, DR | 1 |
| Teodorescu, G | 1 |
| Basson, BR | 1 |
| Piantedosi, FV | 1 |
| Caputo, F | 1 |
| Mazzarella, G | 1 |
| Gilli, M | 1 |
| Pontillo, A | 1 |
| D'Agostino, D | 1 |
| Campbell, S | 1 |
| Marsico, SA | 1 |
| Bianco, A | 1 |
| Vaslamatzis, MM | 1 |
| Rezaï, K | 1 |
| Lokiec, F | 1 |
| Grandjean, I | 1 |
| Weill, S | 1 |
| de Cremoux, P | 1 |
| Bordier, V | 1 |
| Ekue, R | 1 |
| Garcia, M | 1 |
| Poupon, MF | 1 |
| Decaudin, D | 1 |
| Mok, TS | 1 |
| Crowley, J | 1 |
| Gottfried, M | 1 |
| Ramlau, R | 1 |
| Krzakowski, M | 1 |
| Ziolo, G | 1 |
| Olechnowicz, H | 1 |
| Koubkova, L | 1 |
| Dahabreh, J | 1 |
| Szczesna, A | 1 |
| Vivanco, GL | 1 |
| Carpagnano, F | 1 |
| Leong, SS | 3 |
| Fittipaldo, A | 1 |
| De Almeida, C | 1 |
| Grunenwald, D | 1 |
| Carles, J | 3 |
| Ariza, A | 1 |
| Pellicer, I | 1 |
| Fernandez-Vasalo, G | 1 |
| Abad, A | 2 |
| Barnadas, A | 3 |
| Addamo, GF | 1 |
| Borghini, U | 2 |
| Lionetto, R | 1 |
| Conte, PF | 4 |
| Bruzzi, P | 1 |
| Pennucci, MC | 3 |
| Drinkard, LC | 8 |
| Samuels, BL | 8 |
| Watson, S | 6 |
| Bitran, JD | 2 |
| Golomb, HM | 10 |
| Crawford, J | 3 |
| George, M | 1 |
| Masters, GA | 9 |
| Strauss, GM | 2 |
| Lynch, TJ | 3 |
| Elias, AD | 2 |
| Jacobs, C | 2 |
| Kwiatkowski, DJ | 2 |
| Shulman, LN | 1 |
| Carey, RW | 2 |
| Grossbard, ML | 3 |
| Jauss, S | 1 |
| Sugarbaker, DJ | 1 |
| Clerici, M | 2 |
| Figoli, F | 3 |
| Barduagni, M | 1 |
| Carlini, P | 2 |
| Ceci, G | 2 |
| Cortesi, E | 2 |
| Carpi, A | 2 |
| Santini, A | 2 |
| Molina, F | 2 |
| Moreno, I | 4 |
| Martínez, E | 1 |
| Pifarré, A | 1 |
| Font, A | 2 |
| Li, S | 1 |
| Skacel, Z | 2 |
| Gómez-Codina, J | 3 |
| Milroy, R | 1 |
| Macbeth, F | 1 |
| Chang, AY | 2 |
| Asbury, RF | 1 |
| Boros, L | 2 |
| Garrow, GC | 1 |
| Hsieh, S | 1 |
| Miller, VA | 1 |
| Rigas, JR | 2 |
| Pisters, KM | 1 |
| Grant, SC | 1 |
| Pfister, DG | 1 |
| Heelan, RT | 1 |
| Kris, MG | 1 |
| Wagner, W | 1 |
| von Eiff, M | 2 |
| Micke, O | 1 |
| Rübe, C | 2 |
| Willich, N | 1 |
| Cumin, I | 1 |
| Lacroix, H | 1 |
| Mahé, M | 1 |
| Dutin, JP | 1 |
| Dabouis, G | 1 |
| Hayot, M | 1 |
| Rouanet, P | 2 |
| Le Chevalier, T | 3 |
| Michel, FB | 4 |
| Hsieh, RK | 1 |
| Asbury, R | 1 |
| Perez, EA | 2 |
| Sowray, PC | 1 |
| Gardner, SL | 1 |
| Gandara, DR | 2 |
| González Barón, M | 3 |
| Feliu, J | 3 |
| Espinosa, E | 1 |
| García Girón, C | 3 |
| Blanco, E | 1 |
| Garrido, P | 3 |
| Colmenarejo, A | 1 |
| Ordóñez, A | 4 |
| Moyano, A | 1 |
| de la Gándara, I | 1 |
| Kosmidis, P | 2 |
| Skarlos, DV | 1 |
| Samantas, E | 2 |
| Beer, M | 1 |
| Theocharis, D | 1 |
| Zachariadis, E | 1 |
| Gioti, A | 1 |
| Papadakis, E | 1 |
| Poulakis, N | 1 |
| Krigel, RL | 2 |
| Palackdharry, CS | 3 |
| Padavic, K | 1 |
| Haas, N | 1 |
| Kilpatrick, D | 1 |
| Langer, C | 1 |
| Comis, R | 1 |
| Tibaldi, C | 6 |
| Chella, A | 2 |
| Angeletti, CA | 2 |
| Romanini, A | 1 |
| Andrei, A | 2 |
| Algeri, R | 2 |
| Silvano, G | 3 |
| Moro, D | 1 |
| Chastang, C | 2 |
| Jacoulet, P | 1 |
| Paillot, N | 2 |
| Janicot, H | 2 |
| Lombard, JN | 1 |
| Maestre, J | 3 |
| Milla, A | 1 |
| Wolf, M | 3 |
| Hans, K | 2 |
| Becker, H | 3 |
| Hässler, R | 1 |
| von Bültzingslöwen, F | 2 |
| Goerg, R | 1 |
| Klaasen, HA | 1 |
| Dannhäuser, J | 1 |
| Holle, R | 1 |
| Pfab, R | 2 |
| Arcangeli, G | 1 |
| Milano, S | 2 |
| Simoncini, E | 1 |
| Marpicati, P | 1 |
| Millward, MJ | 1 |
| Cantwell, BM | 1 |
| Munro, NC | 1 |
| Robinson, A | 1 |
| Corris, PA | 1 |
| Harris, AL | 1 |
| Graziano, SL | 2 |
| Herndon, JE | 3 |
| Richards, F | 2 |
| DiFino, S | 1 |
| Modeas, C | 1 |
| Duggan, DB | 1 |
| Green, MR | 3 |
| Berrocal, A | 1 |
| Barón, JM | 1 |
| Köpf-Maier, P | 1 |
| Sass, G | 1 |
| Fournel, P | 1 |
| Bohas, CH | 1 |
| Fortune, IC | 1 |
| Chatte, G | 1 |
| Gridelli, C | 2 |
| Rossi, A | 1 |
| Incoronato, P | 1 |
| Bruni, GS | 1 |
| Scognamiglio, F | 1 |
| Ruffolo, P | 1 |
| Rinaldi, L | 1 |
| Bianco, AR | 1 |
| Satoh, H | 1 |
| Yano, H | 1 |
| Ishikawa, H | 1 |
| Hasegawa, S | 1 |
| Majello, E | 1 |
| Johnson, DH | 2 |
| Sohda, T | 1 |
| Urban, T | 2 |
| Bedin, A | 1 |
| Baud, M | 2 |
| Chouaid, C | 1 |
| Febvre, M | 2 |
| Koch, P | 1 |
| Johnson, N | 1 |
| van Schaik, J | 1 |
| Andersen, S | 1 |
| Blatter, J | 3 |
| Bosanquet, N | 1 |
| Copley-Merriman, K | 1 |
| Drings, P | 8 |
| Vandebroek, J | 1 |
| Mariën, S | 1 |
| Roex, L | 1 |
| Bertrand, P | 1 |
| Bockaert, J | 1 |
| De Beukelaar, T | 1 |
| Deman, R | 1 |
| De Muynck, P | 1 |
| Ulrichts, H | 1 |
| Shepherd, FA | 5 |
| Latreille, J | 4 |
| Crump, M | 1 |
| Stewart, D | 3 |
| Tomiak, E | 1 |
| Eisenhauer, E | 3 |
| Fisher, B | 1 |
| Gautier, V | 1 |
| Zinaï, A | 1 |
| Valone, FH | 1 |
| Rege, VB | 1 |
| Clamon, G | 1 |
| Scagliotti, GV | 3 |
| Ricardi, U | 1 |
| Maranzano, E | 1 |
| Morandi, MG | 1 |
| Meacci, L | 1 |
| Marangolo, M | 2 |
| Emiliani, E | 1 |
| Rosti, G | 1 |
| Bolzicco, G | 1 |
| Masiero, P | 1 |
| Gentile, A | 1 |
| Tonato, M | 4 |
| Fountzilas, G | 1 |
| Pavlidis, N | 1 |
| Kattis, K | 1 |
| Skarlos, D | 1 |
| Pawinski, A | 1 |
| Lentz, MA | 1 |
| van Glabbeke, M | 1 |
| van Zandwijk, N | 4 |
| Schnaars, Y | 1 |
| Zatloukal, P | 1 |
| Dolensky, J | 1 |
| Jackevicius, A | 1 |
| Petruzelka, L | 1 |
| Zorzi, F | 1 |
| Ottoni, DB | 1 |
| Di Fabio, D | 1 |
| Mombelloni, G | 1 |
| Palmer, AJ | 1 |
| Brandt, A | 1 |
| Vallejo, C | 1 |
| Romero, A | 1 |
| Perez, J | 1 |
| Cuevas, M | 1 |
| Lacava, J | 1 |
| Sabatini, C | 1 |
| Dominguez, M | 1 |
| Rodriguez, R | 1 |
| Barbieri, M | 1 |
| Romero Acuña, L | 1 |
| Romero Acuña, J | 1 |
| Langhi, M | 1 |
| Amato, S | 1 |
| Salvadori, M | 1 |
| Ortiz, E | 1 |
| Machiavelli, M | 1 |
| Leone, B | 1 |
| Rodenhuis, S | 1 |
| Boerrigter, L | 1 |
| Top, B | 1 |
| Slebos, RJ | 1 |
| Mooi, WJ | 2 |
| van't Veer, L | 1 |
| Paul, K | 2 |
| Salomaa, ER | 1 |
| Liippo, K | 1 |
| Ellmen, J | 1 |
| Komi, J | 1 |
| Planting, AS | 1 |
| de Wit, R | 1 |
| van der Burg, ME | 1 |
| Stoter, G | 1 |
| Verweij, J | 1 |
| Kurowski, V | 1 |
| Wagner, T | 2 |
| Hsieh, A | 1 |
| Mick, R | 1 |
| Guaspari, A | 1 |
| Fetscher, S | 2 |
| Brugger, W | 2 |
| Engelhardt, R | 2 |
| Kanz, L | 2 |
| Hasse, J | 2 |
| Frommhold, H | 2 |
| Wenger, M | 1 |
| Lange, W | 2 |
| Mertelsmann, R | 2 |
| Katschinski, DM | 1 |
| Wiedemann, GJ | 1 |
| Mentzel, M | 1 |
| Mulkerin, DL | 1 |
| Touhidi, R | 1 |
| Robins, HI | 1 |
| Brüggemann, SK | 1 |
| Kisro, J | 1 |
| Eberhard, W | 2 |
| Wilke, HJ | 2 |
| Chomy, F | 2 |
| Chomy, P | 2 |
| Khayat, D | 2 |
| Seeber, S | 2 |
| Mosconi, AM | 2 |
| Morere, JF | 1 |
| Piperno-neumann, S | 1 |
| Brunet, A | 1 |
| Boaziz, C | 1 |
| Kohn, M | 1 |
| Bouillet, T | 1 |
| Breau, JL | 1 |
| Corgna, E | 1 |
| Porrozzi, S | 1 |
| Palladino, MA | 1 |
| Darwish, S | 1 |
| Minotti, V | 1 |
| Semik, M | 1 |
| Masters, G | 1 |
| Rizzi, A | 1 |
| Alghisi, A | 1 |
| Pascarella, A | 1 |
| Bozzola, G | 1 |
| Mutti, S | 1 |
| Herbst, R | 1 |
| Leong, T | 1 |
| Lynch, C | 1 |
| Skarin, AT | 1 |
| Riccardi, F | 1 |
| Cariello, S | 1 |
| Masutani, M | 1 |
| Akusawa, H | 1 |
| Kadota, A | 1 |
| Ohchi, Y | 1 |
| Takahashi, N | 1 |
| Tanigawa, S | 1 |
| Koya, Y | 1 |
| Horie, T | 1 |
| Bureau, G | 4 |
| Zacharias, C | 5 |
| Vansteenkiste, JF | 1 |
| De Leyn, PR | 1 |
| Deneffe, GJ | 1 |
| Lievens, YN | 1 |
| Nackaerts, KL | 1 |
| Van Raemdonck, DE | 1 |
| van der Schueren, E | 1 |
| Lerut, TE | 1 |
| Demedts, MG | 1 |
| Thongprasert, S | 2 |
| Salvati, F | 1 |
| Antilli, A | 1 |
| Barbera, S | 1 |
| Romano, F | 1 |
| Migliorino, MR | 1 |
| Noseda, MA | 1 |
| Crippa, M | 1 |
| Ferrara, G | 2 |
| Raimondi, M | 1 |
| Fioretti, M | 1 |
| Bandera, M | 1 |
| Galeasso, G | 1 |
| Cacciani, GC | 1 |
| Lepidini, G | 1 |
| Sunseri, G | 1 |
| Lanfranco, C | 1 |
| Wyka, D | 1 |
| Golomb, H | 1 |
| Pannacciulli, I | 1 |
| Castello, G | 1 |
| Lerza, R | 1 |
| Botta, M | 1 |
| Arboscello, E | 1 |
| Bogliolo, G | 1 |
| Liu, JM | 2 |
| Wu, MF | 1 |
| Wu, HW | 4 |
| Donnellan, P | 1 |
| Armstrong, J | 1 |
| Rowan, S | 1 |
| Fennelly, D | 1 |
| Lynch, V | 1 |
| McDonnell, T | 1 |
| McNicholas, W | 1 |
| Crown, J | 1 |
| Tsang, KW | 1 |
| Lam, WK | 1 |
| Ip, M | 1 |
| Steward, WP | 1 |
| Rey, F | 1 |
| Astoul, P | 1 |
| Marqueste, L | 1 |
| Petite, JM | 1 |
| Boutin, C | 1 |
| Viallat, JR | 1 |
| Soh, LT | 1 |
| Ang, PT | 3 |
| Spaas, P | 1 |
| Specenier, P | 1 |
| Demedts, M | 1 |
| Preti, P | 2 |
| Poggi, G | 1 |
| Cuomo, AM | 2 |
| Robustelli della Cuna, FS | 2 |
| Zambelli, A | 1 |
| Pavesi, L | 1 |
| Han, JY | 1 |
| Kim, HK | 1 |
| Choi, BG | 1 |
| Moon, H | 1 |
| Hong, YS | 1 |
| Lee, KS | 2 |
| Lafontaine, T | 1 |
| Quantin, X | 2 |
| Reme-Saumon, M | 2 |
| Cupissol, D | 1 |
| Khial, F | 2 |
| Lococo, A | 1 |
| Campisi, C | 1 |
| Lalli, A | 1 |
| Di Lullo, L | 1 |
| De Filippis, S | 2 |
| Vaccarili, M | 1 |
| Zappalà, A | 1 |
| Corrao, G | 1 |
| Rea, S | 2 |
| Baumöhl, J | 3 |
| Levitan, N | 1 |
| Dowlati, A | 1 |
| Craffey, M | 1 |
| Tahsildar, H | 1 |
| MacKay, W | 1 |
| McKenney, J | 1 |
| Remick, SC | 1 |
| Kandioler-Eckersberger, D | 1 |
| Kappel, S | 1 |
| Mittlböck, M | 1 |
| Dekan, G | 1 |
| Ludwig, C | 1 |
| Janschek, E | 1 |
| Wolner, E | 1 |
| Bunn, PA | 1 |
| Deneffe, G | 1 |
| Coosemans, W | 1 |
| Lerut, T | 1 |
| Igami, Y | 1 |
| Yamamoto, R | 1 |
| Wee, J | 2 |
| Fong, KW | 2 |
| Khoo, KS | 2 |
| Fossella, FV | 3 |
| Rigas, J | 1 |
| Tognoni, A | 2 |
| Cadenotti, L | 1 |
| Pensa, F | 2 |
| Vaira, F | 2 |
| Vigani, A | 2 |
| Bancalari, L | 2 |
| Cordani, S | 1 |
| Maggiani, R | 2 |
| Canessa, PA | 1 |
| Pronzato, P | 3 |
| Woodroffe, CM | 3 |
| Chetiyawardana, AD | 2 |
| Joshi, R | 2 |
| Cook, JE | 1 |
| Trask, C | 1 |
| Bessell, E | 1 |
| Connolly, CK | 1 |
| Tobias, J | 1 |
| Souhami, RL | 2 |
| Ricci, S | 1 |
| Ceribelli, A | 1 |
| Bianco, R | 1 |
| Sassi, M | 2 |
| Barni, S | 1 |
| Ravaioli, A | 1 |
| Adamo, V | 1 |
| Cruciani, G | 1 |
| Masotti, A | 1 |
| Gozzelino, F | 1 |
| Javier Sánchez, J | 1 |
| Padilla, J | 1 |
| Cantó, A | 1 |
| Roig, J | 1 |
| Scinto, AF | 1 |
| Ferraresi, V | 1 |
| Milella, M | 1 |
| Tucci, E | 1 |
| Santomaggio, C | 1 |
| Pasquali-Lasagni, R | 1 |
| Del Vecchio, MR | 1 |
| Campioni, N | 1 |
| Nardi, M | 1 |
| Cognetti, F | 1 |
| Martin, C | 1 |
| Balaña, C | 1 |
| Socinski, MA | 1 |
| Langer, CJ | 1 |
| Fossella, F | 1 |
| Belani, CP | 1 |
| Corsi, DC | 1 |
| Pozzo, C | 1 |
| Cassano, A | 1 |
| Alvaro, G | 1 |
| Colloca, G | 1 |
| Landriscina, M | 1 |
| Astone, A | 1 |
| Vergnenègre, A | 1 |
| Thomas, P | 1 |
| Robinet, G | 1 |
| Pibarot, M | 1 |
| Paillotin, D | 1 |
| Vernejoux, JM | 1 |
| Thiberville, L | 2 |
| Lena, H | 1 |
| Kleisbauer, JP | 1 |
| Gimonet, JF | 1 |
| Tan, T | 1 |
| Eng, P | 1 |
| Hsu, A | 1 |
| Tan, YK | 1 |
| Chua, EJ | 1 |
| Ong, YY | 1 |
| Rosselli, M | 1 |
| Pompili, P | 1 |
| Guerriero, G | 1 |
| Yang, KY | 2 |
| Campoccia, S | 1 |
| Cionini, L | 1 |
| Conte, P | 1 |
| Perry, MC | 1 |
| Ihde, DC | 1 |
| Grethein, SJ | 1 |
| Atkins, JN | 1 |
| Vadell-Nadal, C | 1 |
| Nogué-Aliguer, M | 1 |
| Fabregat-Mayol, X | 1 |
| Saigí-Grau, E | 1 |
| Gallén-Castillo, M | 1 |
| DeVore, R | 1 |
| Kerr, RN | 1 |
| Natale, RR | 1 |
| Dunphy, F | 1 |
| Kalman, L | 1 |
| Miller, V | 1 |
| Moore, M | 1 |
| Gandara, D | 1 |
| Karp, D | 1 |
| Vokes, E | 1 |
| Kris, M | 1 |
| Kim, Y | 1 |
| Gamza, F | 1 |
| Hammershaimb, L | 1 |
| Takigawa, N | 2 |
| Segawa, Y | 3 |
| Kishino, D | 1 |
| Fujiwara, K | 1 |
| Ida, M | 1 |
| Eguchi, K | 1 |
| Takamori, S | 1 |
| Hayashi, A | 1 |
| Tayama, K | 1 |
| Mitsuoka, M | 1 |
| Fujimoto, K | 1 |
| Horiuchi, M | 1 |
| Hayabuchi, N | 1 |
| Oizumi, K | 1 |
| Shirouzu, K | 1 |
| Bisagni, G | 1 |
| Savoldi, L | 1 |
| Moretti, G | 1 |
| Rondini, E | 1 |
| Zadro, A | 1 |
| De Pas, T | 1 |
| Franciosi, V | 1 |
| Pazzola, A | 1 |
| Vignoli, R | 1 |
| Banzi, MC | 1 |
| Pajetta, V | 1 |
| Tsavaris, NB | 3 |
| Sepsas, E | 2 |
| Malamos, NA | 2 |
| Vadiaka, M | 4 |
| Dosios, T | 1 |
| Antonopoulos, MJ | 1 |
| Chen, Y | 1 |
| Sandler, A | 1 |
| Schmerber, J | 1 |
| Sayit, E | 1 |
| Aktoğu, S | 1 |
| Ertay, T | 1 |
| Capa, G | 1 |
| Erkmen, G | 1 |
| Ozbilek, E | 1 |
| Büyükşirin, M | 1 |
| Durak, H | 1 |
| Koufos, C | 1 |
| Gérinière, L | 1 |
| Takita, H | 2 |
| Pitoniak, RF | 1 |
| Ahn, JB | 1 |
| Ko, WK | 1 |
| Lee, JG | 1 |
| Shim, KY | 1 |
| Jeung, HC | 1 |
| Park, JO | 1 |
| Yoo, NC | 1 |
| Kim, BS | 1 |
| Kim, SK | 2 |
| Czownicki, Z | 1 |
| Pasz, P | 1 |
| Michałek, A | 1 |
| Zientek, J | 1 |
| Zientek, A | 1 |
| Koźlik, H | 1 |
| Shin, KH | 1 |
| Dingemans, AC | 1 |
| van Ark-Otte, J | 1 |
| Span, S | 1 |
| van der Valk, P | 1 |
| Postmus, PE | 1 |
| Fiasella, L | 1 |
| Canessa, P | 1 |
| Arnau Obrer, A | 2 |
| Martín Díaz, E | 2 |
| Pérez Alonso, D | 2 |
| Regueiro Mira, F | 2 |
| Cervera Juan, A | 2 |
| Granell Gil, M | 2 |
| Roch Pendería, S | 1 |
| Cantó Armengod, A | 2 |
| Panopoulos, C | 1 |
| Stavroyianni, N | 2 |
| Kourelis, T | 1 |
| Malamos, N | 1 |
| Antonopoulos, M | 1 |
| Cañizares Carretero, M | 1 |
| Roch Tejerina, S | 1 |
| Kobylińska, K | 1 |
| Koralewski, P | 1 |
| Sobik, B | 1 |
| Gasiorek, M | 1 |
| Kobylińska, M | 1 |
| Rixe, O | 1 |
| Le Guen, Y | 1 |
| Touboul, E | 1 |
| Baiardi, P | 1 |
| Torazzo, R | 1 |
| Robustelli della Cuna, G | 1 |
| Montalar, J | 1 |
| Maestu, I | 1 |
| García, R | 1 |
| Yuste, AL | 1 |
| Torregrosa, D | 1 |
| Segura, A | 1 |
| Erkisi, M | 1 |
| Erkurt, E | 1 |
| Zeren, H | 1 |
| Tunali, C | 1 |
| Kocabas, A | 1 |
| Burgut, R | 1 |
| Neumaier, C | 1 |
| Tumolo, S | 1 |
| Toffoli, G | 1 |
| Saracchini, S | 1 |
| Lo Re, G | 1 |
| Bruschi, G | 1 |
| Boccieri, MG | 1 |
| Chevret, S | 1 |
| Lemarié, E | 1 |
| Gouva, S | 1 |
| Bréchot, JM | 1 |
| Terrioux, P | 1 |
| Clavier, J | 1 |
| Foucher, P | 1 |
| Monchâtre, M | 1 |
| Coëtmeur, D | 1 |
| Leclerc, P | 1 |
| Blanchon, F | 1 |
| Rodier, JM | 1 |
| Villeneuve, A | 1 |
| Onyenadum, A | 1 |
| Dimitropoulos, D | 1 |
| Rokana, S | 1 |
| Chu, DT | 1 |
| Zhang, XR | 1 |
| Li, JL | 1 |
| Qu, FL | 1 |
| Sun, Y | 1 |
| Kodani, T | 2 |
| Ueoka, H | 4 |
| Kiura, K | 2 |
| Tabata, M | 2 |
| Moritaka, T | 2 |
| Hiraki, S | 3 |
| Harada, M | 1 |
| Tanimoto, M | 1 |
| Hosomi, Y | 1 |
| Shibuya, M | 1 |
| Nakabayashi, T | 1 |
| Miyamoto, H | 1 |
| Fujikane, T | 1 |
| Shimizu, T | 1 |
| Yasuda, S | 1 |
| Akita, H | 1 |
| Sakai, E | 1 |
| Onodera, S | 1 |
| Ohsaki, Y | 1 |
| Kawakami, Y | 1 |
| Zamora, P | 1 |
| Garcia de Paredes, ML | 1 |
| Chacon, JI | 1 |
| Eberhardt, W | 1 |
| Niederle, N | 1 |
| Shirinian, M | 2 |
| Dhingra, HH | 2 |
| Greenberg, J | 2 |
| Hong, WK | 3 |
| Evans, WK | 2 |
| Goss, PE | 2 |
| Logan, D | 2 |
| Maroun, J | 2 |
| Warner, E | 2 |
| Jassem, E | 1 |
| Bonfrer, JM | 1 |
| van Tinteren, H | 2 |
| Bischoff, H | 1 |
| Fischer, JR | 1 |
| Löchner, S | 1 |
| Peukert, M | 1 |
| Schmähl, A | 1 |
| Smith, IE | 1 |
| Gurney, H | 2 |
| de Campos, ES | 1 |
| Dodwell, D | 1 |
| Kamthan, A | 2 |
| Lind, MJ | 3 |
| Gomm, S | 1 |
| Simmonds, AP | 1 |
| Weiss, RB | 1 |
| Heckmayr, M | 2 |
| Hossfeld, DK | 2 |
| Kaukel, E | 2 |
| Koschel, G | 2 |
| Neuhauss, R | 2 |
| von Rohr, A | 1 |
| McIntosh, R | 1 |
| Ohnoshi, T | 3 |
| Ueda, N | 1 |
| Fujii, M | 2 |
| Machida, K | 1 |
| Kawahara, S | 2 |
| Kozuka, A | 1 |
| Maasberg, M | 2 |
| Havemann, K | 2 |
| Mariani, GL | 1 |
| Addamo, G | 1 |
| Venturini, M | 1 |
| Kamei, H | 1 |
| Kimura, I | 1 |
| Sasaki, H | 1 |
| Mori, T | 1 |
| Nakajima, S | 1 |
| Inoue, Y | 2 |
| Honda, R | 2 |
| Asakawa, M | 2 |
| Suzuki, A | 2 |
| Gomm, SA | 1 |
| Cuthbert, A | 1 |
| Chang, J | 1 |
| Burmester, H | 1 |
| Hall, P | 1 |
| Carroll, KB | 1 |
| ten Bokkel Huinink, WW | 1 |
| Wanders, J | 1 |
| Simonetti, G | 1 |
| Dubbelman, R | 1 |
| Franklin, H | 1 |
| McVie, JG | 1 |
| Currie, DC | 1 |
| Miles, DW | 1 |
| Drake, JS | 1 |
| Rudd, R | 1 |
| Earl, HM | 1 |
| Tobias, JS | 1 |
| Holoye, PY | 2 |
| Glisson, BS | 1 |
| Dhingra, HM | 1 |
| Murphy, WK | 1 |
| Umsawasdi, T | 1 |
| Levy, JK | 1 |
| Jeffries, D | 1 |
| Raber, MN | 1 |
| Abad-Esteve, A | 2 |
| Fernandez, C | 1 |
| Ribelles, N | 2 |
| Culubret, M | 1 |
| Matsutomo, S | 1 |
| Genba, K | 1 |
| Itami, S | 1 |
| Ogawa, M | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Mukaiyama, T | 1 |
| Fukutani, H | 1 |
| Hirano, A | 1 |
| Mizunuma, N | 1 |
| Nakagawa, K | 1 |
| Paccagnella, A | 1 |
| Favaretto, A | 1 |
| Brandes, A | 1 |
| Ghiotto, C | 1 |
| Fornasiero, A | 1 |
| Volpi, A | 1 |
| Pappagallo, G | 1 |
| Festi, G | 1 |
| Cipriani, A | 1 |
| Vinante, O | 1 |
| Laumen, R | 1 |
| Jungbluth, H | 1 |
| von Pawel, J | 1 |
| Häussinger, K | 1 |
| Otto, M | 1 |
| Krieger, H | 1 |
| Margison, JM | 2 |
| Cerny, T | 2 |
| Wilkinson, PM | 2 |
| Olazabal, A | 1 |
| Canela, M | 1 |
| Bidoli, P | 1 |
| Spinazzè, S | 1 |
| Santoro, A | 1 |
| Casali, P | 1 |
| Bedini, AV | 1 |
| Guzzon, A | 1 |
| Rossi, JF | 1 |
| Dubois, JB | 1 |
| Arriagada, R | 2 |
| Mary, H | 1 |
| Godard, P | 1 |
| Saito, H | 2 |
| Shimokata, K | 1 |
| Yamamoto, M | 1 |
| Saka, H | 1 |
| Sakai, S | 1 |
| Kawachi, H | 1 |
| Ettinger, DS | 1 |
| Chetiyawardana, SD | 1 |
| Joshi, RC | 1 |
| Fusco, V | 1 |
| Gulisano, M | 1 |
| Baracco, F | 1 |
| Capaccio, A | 1 |
| Pastorino, G | 1 |
| Nosenzo, M | 1 |
| Felletti, R | 1 |
| Fabiano, F | 1 |
| Tamura, T | 1 |
| Yonei, T | 1 |
| Yamashita, H | 1 |
| Ishii, J | 1 |
| Tamai, M | 1 |
| Egawa, T | 1 |
| Pastran, Z | 1 |
| Baldeyrou, P | 1 |
| Spielmann, M | 1 |
| Droz, JP | 1 |
| Rouesse, J | 1 |
| Stalleicken, D | 1 |
| Gropp, C | 1 |
| Klasen, H | 1 |
| Schroeder, M | 1 |
| Bülzebruck, H | 1 |
| Djawid, N | 1 |
| Ruchalla, E | 1 |
| Stiefel, P | 1 |
| Tessen, HW | 1 |
| Carmichael, J | 1 |
| Fergusson, RJ | 1 |
| Wolf, CR | 1 |
| Balkwill, FR | 1 |
| Smyth, JF | 1 |
| Girón, CG | 1 |
| Jalón, JI | 1 |
| Barón, MG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen[NCT02133196] | Phase 2 | 85 participants (Anticipated) | Interventional | 2014-10-23 | Recruiting | ||
| Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC[NCT00198354] | Phase 3 | 530 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer[NCT01441128] | Phase 1 | 20 participants (Actual) | Interventional | 2011-09-01 | Terminated | ||
| Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer[NCT00005055] | Phase 2 | 39 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients[NCT01749072] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)[NCT02734069] | 132 participants (Anticipated) | Observational | 2016-02-29 | Recruiting | |||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC[NCT00923273] | Phase 1/Phase 2 | 42 participants (Actual) | Interventional | 2008-02-29 | Terminated (stopped due to Premature closure - investigator left the National Institutes of Health.) | ||
| A Study on the Efficacy and Safety of Anlotinib Combined With Docetaxel in the Treatment of Wild-type Advanced Non-squamous Non Small Cell Lung Cancer Patients With Progress After Immunotherapy Plus Chemotherapy as First-line Treatment[NCT04619537] | Phase 2 | 42 participants (Anticipated) | Interventional | 2020-10-08 | Recruiting | ||
| Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies[NCT00703625] | Phase 1 | 26 participants (Actual) | Interventional | 2008-03-08 | Completed | ||
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167] | Phase 2 | 1 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Lack of accrual and interest in study) | ||
| A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR[NCT01755923] | Phase 2 | 60 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.[NCT02259621] | Phase 2 | 45 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
The phase I component of the study are to determine the safety and tolerability of pemetrexed in human subjects with non small cell lung cancer (NSCLC), and to determine the maximum tolerated dose. (NCT00923273)
Timeframe: 5 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| Treatment Level 1: 3mg Load | 500 |
| Treatment Level 2: 6mg Load | 500 |
| Treatment Level 3: 6mg Load | 500 |
| Treatment Level 4: 10mg Load | 500 |
| Treatment Level 5: 15mg Load | 500 |
The phase I component of the study are to determine the safety and tolerability of sirolimus in human subjects with non small cell lung cancer (NSCLC), and to determine the maximum tolerated dose. (NCT00923273)
Timeframe: 5 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| Treatment Level 1: 3mg Load | 10 |
| Treatment Level 2: 6mg Load | 10 |
| Treatment Level 3: 6mg Load | 10 |
| Treatment Level 4: 10mg Load | 10 |
| Treatment Level 5: 15mg Load | 10 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00923273)
Timeframe: Date treatment consent signed to date off study, approximately 45 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Subjects from phase I | 8subjects prior peme & 12 subjects peme naive | |
| Treatment Level 1: 3mg Load | 4 | 0 |
| Treatment Level 2: 6mg Load | 3 | 0 |
| Treatment Level 3: 6mg Load | 3 | 0 |
| Treatment Level 4: 10 mg Load | 7 | 20 |
| Treatment Level 5: 15mg Load | 5 | 0 |
Clinical response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00923273)
Timeframe: 21 weeks
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | Not evaluable | |
| Treatment Level 4: 10mg Load | 0 | 5 | 13 | 2 | 7 |
33 reviews available for ifosfamide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2003 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non- | 2006 |
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinica | 1995 |
Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1995 |
Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1995 |
Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical | 1994 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1996 |
The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 1996 |
Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinica | 1998 |
A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as T | 1998 |
Ifosfamide and docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Pha | 1998 |
Combination studies with gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1998 |
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as T | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycy | 1999 |
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1999 |
New options in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 1999 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell | 2000 |
Second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung | 2000 |
[Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopl | 2000 |
Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Ca | 2001 |
The treatment of advanced non-small-cell lung cancer (NSCLC)--overseas updated and local experiences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical | 2002 |
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycy | 2002 |
[ Early anti-cancer drugs].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2002 |
Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical | 1992 |
Ifosfamide in non-small cell lung cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Th | 1992 |
A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
Overview of ifosfamide in small cell and non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cel | 1990 |
Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modal | 1990 |
Ifosfamide in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Th | 1989 |
181 trials available for ifosfamide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; | 2013 |
Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2013 |
An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2013 |
[Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2015 |
Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Humans; Ifosfamide; Lung Neoplasms; Mice; Nitroimidazoles; | 2016 |
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2012 |
Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2012 |
Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino | 2012 |
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Belg | 2002 |
Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cos | 2002 |
[Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2002 |
GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2002 |
[Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel | 2002 |
Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 2003 |
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2003 |
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; C | 2003 |
Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2003 |
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2003 |
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2003 |
Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2004 |
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino | 2004 |
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Child; Child, Presch | 2004 |
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2004 |
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2005 |
Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2005 |
Chemotherapy for metastatic NSCLC: current status and future direction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2005 |
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small- | 2005 |
A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, No | 2005 |
Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchoscopy; Carcinoma, Non-Sm | 2005 |
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2006 |
Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2006 |
Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Non-Small-Cell Lung | 2006 |
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deo | 2007 |
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycy | 2008 |
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; | 2007 |
Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 2008 |
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1995 |
Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Ad | 1995 |
Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-C | 1995 |
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, No | 1995 |
Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Eto | 1995 |
Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1995 |
Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1995 |
Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1995 |
Ifosfamide/carboplatin/etoposide chemotherapy in patients with metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1995 |
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Eto | 1995 |
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Resp | 1995 |
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronc | 1995 |
Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 1994 |
Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1994 |
Phase I study of high-dose cisplatin, ifosfamide, and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dru | 1994 |
Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. A study of the Hellenic Co-operative Oncology Group for Lung Cancer Trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1994 |
Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
An ongoing randomized study of neoadjuvant chemotherapy in resectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1994 |
A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 1994 |
Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1994 |
Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dr | 1994 |
MICE: a new active combination for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1993 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1993 |
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1993 |
Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-C | 1993 |
Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 1996 |
Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response | 1996 |
Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Ifosfa | 1996 |
Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
[Evaluation of chemotherapy for stage IV non-small cell lung cancer employing a regression tree type method for quality-adjusted survival analysis to determine prognostic factors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1996 |
Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; | 1996 |
Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 1995 |
Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; | 1996 |
Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Th | 1996 |
r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dru | 1996 |
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Admi | 1996 |
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
[Phase I study of cisplatin, ifosfamide and CPT11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 1996 |
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1996 |
Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administr | 1996 |
Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carci | 1997 |
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Bronchoge | 1997 |
Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Ad | 1997 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; C | 1997 |
Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Breast Neoplasms; Carboplatin; Car | 1997 |
A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 1997 |
Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, No | 1997 |
Vinorelbine and ifosfamide for unresectable non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administr | 1997 |
A better therapeutic profile for the combination of mitomycin-C, ifosfamide and cisplatin (MIC) in advanced non-small-cell lung cancer: a useful dose-schedule modification.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1997 |
[Neoadjuvant combined therapy in stage IIIA if non-small-cell bronchial cancer].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1997 |
Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Ad | 1997 |
Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1997 |
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1997 |
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1997 |
A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cel | 1996 |
Ifosfamide-based three-drug combination regimens in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Granulo | 1998 |
Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Femal | 1998 |
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1998 |
Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1998 |
Phase II study of paclitaxel (Taxol) and ifosfamide (Holoxan) in inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; | 1998 |
Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1998 |
A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 1998 |
Cisplatin inhibits erythroid committed progenitor (BFU-E) mobilization in peripheral blood.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1998 |
Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino | 1998 |
New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1998 |
Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1998 |
Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dru | 1998 |
Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1998 |
Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC).
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1998 |
Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Carboplatin, ifosfamide, and vinorelbine in the treatment of advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1999 |
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Ca | 1998 |
Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1999 |
A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Workin
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1999 |
Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combine | 1999 |
[Period of time patients with advanced non-small cell lung cancer could remain at home during CIC--therapy (cisplatin + ifosfamide + CPT-11)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 1999 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Ifosfamide; Lung Neoplasms | 1999 |
A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1999 |
Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1999 |
Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Vinorelbine and alternating cisplatin and ifosfamide in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2000 |
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1999 |
[High-dose ifosfamide in patients with stage IV non-small cell lung cancer: phase II trial from the Groupe français de pneumo-cancérologie (GFPC)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Female; Humans; Ifos | 1999 |
Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycy | 1999 |
A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epi | 2000 |
Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2000 |
A phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2000 |
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 2000 |
Effect of chemotherapy on pulmonary epithelial permeability in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Gas Analysis; Carcinoma, Non-Small-Cell Lung; | 2000 |
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell | 2001 |
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
[Use of etoposide, ifosfamide and cisplatin (EIP) for treatment of inoperable non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Eto | 2000 |
Radiation induced chemotherapy sensitization in trimodality therapy of stage III non small cell lung cancer. A preliminary report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2000 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2001 |
Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Blood Cell Count; B | 2001 |
Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2001 |
Anticipated administration of GM-CSF in the treatment of non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2001 |
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycy | 2001 |
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2002 |
The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fem | 2001 |
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2002 |
A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Squ | 2002 |
[Randomized trial of cisplatin plus ifosfamide versus cisplatin plus vindesine for non-small cell lung cancer (NSCLC)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dru | 1992 |
Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1992 |
A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1991 |
Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell | 1991 |
[Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Topics: Adenocarcinoma; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, No | 1990 |
High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Non-S | 1991 |
A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1990 |
[Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide | 1990 |
Ifosfamide, cisplatin, vinblastine combination chemotherapy in the treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
[Results of 2 multicenter therapy studies in inoperable non-small cell bronchial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical | 1988 |
"Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial".
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc | 1987 |
78 other studies available for ifosfamide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2013 |
Two consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Doxorub | 2011 |
Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 2002 |
Neo-adjuvant chemotherapy in early stages of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2002 |
Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2003 |
[Cellular changes in non-small cell lung cancer after neoadjuvant therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Ce | 2004 |
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2004 |
Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Databases | 2005 |
[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 2005 |
Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; I | 2005 |
The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysi
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 2006 |
[Current data concerning neoadjuvant chemotherapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 2006 |
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2006 |
[Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide | 2006 |
[Role of radiotherapy of lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2006 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinica | 2006 |
Chemotherapy improves low performance status lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female | 2007 |
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Carcinoma, Non-Small- | 2007 |
Big question, small answer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Admi | 2008 |
Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemothe | 1993 |
[Efficacy of the combination of mitomycin, ifosfamide and cisplatin with irradiation for the treatment of cerebral metastasis in non small cell lung carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 1995 |
Antitumor activity of treosulfan in human lung carcinomas.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 1996 |
Disease extent and response to chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 1996 |
Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1995 |
Histopathological grading of response to induction chemotherapy in non-small cell lung cancer: a preliminary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 1996 |
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Gene Ex | 1997 |
Gemcitabine shows promise as combination agent in NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcin | 1996 |
Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide.
Topics: Acetaldehyde; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cells, Cultured; Dose-Response Relation | 1997 |
Response of dermatomyositis co-existing with non-small cell lung cancer to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dermatomy | 1998 |
Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 1998 |
Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1998 |
The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies | 1999 |
Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 1999 |
[Combination chemotherapy consisting of ifosfamide and vindesine for non-small cell lung cancer in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2000 |
Induction chemotherapy for locoregional lung cancer using paclitaxel combination. A preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2000 |
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Bin | 2001 |
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deo | 2001 |
[Surgical treatment of non-small cell lung cancer with mediastinal node invasion. A retrospective study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2001 |
[Surgery and combined therapy for non-small cell lung cancer with invasion of the mediastinal nodes. A retrospective study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2001 |
[Chemoradiotherapy-chemotherapy for grade III inoperable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2001 |
Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ICE regimen) in advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2001 |
Docetaxel and non small-cell lung cancer: new indication. One of several non curative chemotherapies.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical | 2001 |
Managing poor performance non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; I | 2001 |
[Advances in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1992 |
Analysis of the four combination chemotherapies in non-small cell lung cancer treated at Maharaj Nakorn Chiang Mai Hospital.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1992 |
Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma | 1992 |
Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcino | 1992 |
Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dreams; Drug Administration Schedule; Female; Humans; Ifosfami | 1992 |
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1991 |
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; Ifosfamide; Interferon | 1991 |
Ifosfamide vs cyclophosphamide in cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms, | 1991 |
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; D | 1991 |
Combined chemo- and radiosensitivity testing with ifosfamide and ACNU in human lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cel | 1991 |
A pilot study of mitomycin, ifosfamide and cisplatin as outpatient combination chemotherapy for advanced non-small cell lung cancer.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1991 |
[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1990 |
Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
Ifosfamide with mesna uroprotection in the management of lung cancer.
Topics: Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans | 1990 |
A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
[Phase II study of ifosfamide and vindesine combination of non-small cell lung cancer in elderly patients and patients with reduced renal function].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 1990 |
[Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1990 |
[Polychemotherapy of non-small cell bronchial cancer with mitomycin C, ifosfamide and vindesine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration | 1990 |
The effect of age on the pharmacokinetics of ifosfamide.
Topics: Adult; Aged; Aging; Body Water; Carcinoma, Non-Small-Cell Lung; Half-Life; Humans; Ifosfamide; Lung | 1990 |
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sma | 1990 |
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
European experience with ifosfamide in non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dr | 1989 |
Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1989 |
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromat | 1989 |
Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1987 |
[Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1988 |
Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Ev | 1988 |
Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1988 |
[Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1988 |
Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; | 1986 |
Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1987 |